ES2541488T3 - Espuma farmacéutica penetrante - Google Patents
Espuma farmacéutica penetrante Download PDFInfo
- Publication number
- ES2541488T3 ES2541488T3 ES11190124.5T ES11190124T ES2541488T3 ES 2541488 T3 ES2541488 T3 ES 2541488T3 ES 11190124 T ES11190124 T ES 11190124T ES 2541488 T3 ES2541488 T3 ES 2541488T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- polymers
- weight
- gum
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008255 pharmaceutical foam Substances 0.000 title description 3
- 230000000149 penetrating effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract description 19
- -1 polyoxyethylene Polymers 0.000 abstract description 8
- 239000002904 solvent Substances 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 239000004094 surface-active agent Substances 0.000 abstract description 5
- 239000003349 gelling agent Substances 0.000 abstract description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003380 propellant Substances 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 2
- 239000003623 enhancer Substances 0.000 abstract description 2
- 239000000194 fatty acid Substances 0.000 abstract description 2
- 229930195729 fatty acid Natural products 0.000 abstract description 2
- 235000010493 xanthan gum Nutrition 0.000 abstract description 2
- 239000000230 xanthan gum Substances 0.000 abstract description 2
- 229920001285 xanthan gum Polymers 0.000 abstract description 2
- 229940082509 xanthan gum Drugs 0.000 abstract description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
- 229920000642 polymer Polymers 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 229920000881 Modified starch Polymers 0.000 abstract 3
- 235000019426 modified starch Nutrition 0.000 abstract 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 2
- 229920002125 Sokalan® Polymers 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 2
- 125000002091 cationic group Chemical group 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 239000000839 emulsion Substances 0.000 abstract 2
- 239000000600 sorbitol Substances 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 abstract 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 abstract 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 abstract 1
- 229920001817 Agar Polymers 0.000 abstract 1
- 241000416162 Astragalus gummifer Species 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000011632 Caseins Human genes 0.000 abstract 1
- 108010076119 Caseins Proteins 0.000 abstract 1
- 244000303965 Cyamopsis psoralioides Species 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 229920002907 Guar gum Polymers 0.000 abstract 1
- 229920000161 Locust bean gum Polymers 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 108010058846 Ovalbumin Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Chemical group 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 abstract 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 229920001615 Tragacanth Polymers 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 239000008272 agar Substances 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 abstract 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical class OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 235000010418 carrageenan Nutrition 0.000 abstract 1
- 239000000679 carrageenan Substances 0.000 abstract 1
- 229920001525 carrageenan Polymers 0.000 abstract 1
- 229940113118 carrageenan Drugs 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 229920003086 cellulose ether Polymers 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 235000010417 guar gum Nutrition 0.000 abstract 1
- 239000000665 guar gum Substances 0.000 abstract 1
- 229960002154 guar gum Drugs 0.000 abstract 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 abstract 1
- 229940113096 isoceteth 20 Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 235000010420 locust bean gum Nutrition 0.000 abstract 1
- 239000000711 locust bean gum Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 abstract 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 1
- 229920001223 polyethylene glycol Chemical group 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 229940068965 polysorbates Drugs 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 229940068984 polyvinyl alcohol Drugs 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229920000915 polyvinyl chloride Polymers 0.000 abstract 1
- 239000004800 polyvinyl chloride Substances 0.000 abstract 1
- 239000005033 polyvinylidene chloride Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 abstract 1
- 229920005573 silicon-containing polymer Polymers 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 229940080237 sodium caseinate Drugs 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 abstract 1
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 abstract 1
- 150000003445 sucroses Chemical class 0.000 abstract 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000003352 sequestering agent Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229940098330 gamma linoleic acid Drugs 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 229940075554 sorbate Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Chemical class 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- GSTSUZHIVMCRLR-RVZXSAGBSA-N (2s)-2,6-diaminohexanoic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.NCCCC[C@H](N)C(O)=O GSTSUZHIVMCRLR-RVZXSAGBSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 150000001536 azelaic acids Chemical class 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008260 cosmetic foam Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- FVCOIAYSJZGECG-UHFFFAOYSA-N diethylhydroxylamine Chemical compound CCN(O)CC FVCOIAYSJZGECG-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 150000005165 hydroxybenzoic acids Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229960004738 nicotinyl alcohol Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/16—Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una emulsión de aceite en agua espumable que es estable en su estado pre-dispensado, que comprende: (i) 4.5 - 55% en peso de la composición de un solvente no volátil que, de 20-30 °C, es líquido y tiene una solubilidad en agua destilada de menos de 1 g por 100 ml; (ii) 0.09 a 5.5% en peso de la composición del agente tensoactivo seleccionado del grupo que consiste en polisorbatos, ésteres de ácidos grasos de polioxietileno (POE), éteres de alquilo de poli (oxietileno), ésteres de sacarosa, ésteres parciales de sorbitol y anhídridos de sorbitol, mono o diglicéridos, isoceteth-20, metil cocoil taurato de sodio, metil oleil taurato de sodio, lauril sulfato de sodio, lauril sulfato de trietanolamina y betaínas; (iii) 0.09-5.5% en peso del agente gelificante seleccionado del grupo que consiste en goma de algarroba, alginato sódico, caseinato sódico, albúmina de huevo, agar gelatina, goma carragenina, goma xantana, extracto de semilla de membrillo, goma tragacanto, almidón, almidones modificados químicamente, éteres de celulosa, celulosa micro-cristalina, alcohol polivinílico, goma guar, goma guar de hidroxipropilo, almidón soluble, celulosas catiónicas, gomas guar catiónicas, polímeros de carboxivinilo, polivinilpirrolidona, polímeros de ácido poliacrílico, polímeros de ácido polimetacrílico, polímeros de acetato de polivinilo, polímeros de cloruro de polivinilo, polímeros de cloruro de polivinilideno, copolímeros de ácido acrílico/acrilato de etilo, copolímero de acrilato, polímeros de silicona, derivados acetilados de almidón, almidones modificados anfifílicos, copolímeros de bloques anfifílicos de óxido de etileno, óxido de propileno y/o propilen glicol; y cualquier combinación de los mismos; (iv) un potenciador terapéutico seleccionado del grupo que consiste en propilen glicol, glicoles de butileno, glicerol, pentaeritritol, sorbitol, manitol, oligosacáridos, dimetil isosorbida, monooleato de glicéridos etoxilados que tienen de 8 a 10 unidades de óxido de etileno, polietilen glicol 200-600, Transcutol , glicofurol y ciclodextrinas; (v) una concentración terapéuticamente eficaz de ácido azelaico; y (vi) un propelente de gas licuado a una concentración de 2.7% a 19.8% en peso de la composición total; en donde la emulsión contiene no más del 7.5% en peso de cualquier alcohol alifático, que tiene uno a seis átomos de carbono en su esqueleto de carbono.
Description
5
10
15
20
25
30
35
40
45
50
55
60
E11190124
02-07-2015
acondicionadores de la piel (por ejemplo, humectantes, incluyendo misceláneos y humectantes que facilitan la regulación de la residencia de un agente activo en la piel), agentes de curación y/o calmantes de la piel (por ejemplo, pantenol y derivados (por ejemplo, etil pantenol), aloe vera, ácido pantoténico y derivados del ácido pantoténico, alantoína, bisabolol y glicirricinato dipotásico), agentes de tratamiento de la piel, espesantes calmantes, y vitaminas y derivados de los mismos.
Agentes activos anti-acné
Aparte del ácido azelaico, un agente anti-acné se puede incluir en la composición espumable. El agente anti-acné se puede seleccionar del grupo que consiste de resorcinol, azufre, ácido salicílico y salicilatos, ácidos alfa-hidroxi, agentes antiinflamatorios no esteroideos, peróxido de benzoilo, ácido retinoico, ácido isoretinoico y otros compuestos retinoides, adapaleno, el tazaroteno, derivados de ácido azelaico, agentes antibióticos, tales como la eritromicina y clindamicina, sales de zinc y complejos, y combinaciones de los mismos, en una concentración terapéuticamente eficaz.
Agentes activos antiarrugas/agentes activos anti-atrofia y agentes para tratar la piel seca y escamosa (xerosis e ictiosis)
La composición espumable también puede incluir una cantidad eficaz de un activo anti-arrugas y/o al menos un activo antiatrofias. Ejemplos de agentes activos anti-arrugas/anti-atrofia apropiados para uso en las composiciones espumables incluyen D y L aminoácidos que contienen azufre y sus derivados y sales, particularmente los derivados de N-acetilo; tioles; ácidos hidroxi (por ejemplo, ácidos alfa-hidroxi tales como ácido láctico y ácido glicólico y sus derivados y sales, o ácidos betahidroxi tales como el ácido salicílico y sales del ácido salicílico y derivados), urea, ácido hialurónico, ácido fítico, ácido lipoico; ácido lisofosfatídico, agentes de exfoliación de la piel (por ejemplo, fenol, resorcinol y similares), compuestos de vitamina B3 (por ejemplo, niacinamida, ácido nicotínico y sales y ésteres del ácido nicotínico, incluyendo ésteres no vasodilatadores del ácido nicotínico (tales como nicotinato de tocoferilo), nicotinil aminoácidos, ésteres de alcohol nicotinílico de ácidos carboxílicos, N-óxido del ácido nicotínico y N-óxido de niacinamida), vitamina B5 y retinoides (por ejemplo, retinol, retinal, ácido retinoico, acetato de retinilo, palmitato de retinilo, ascorbato de retinilo). En el caso de la piel seca y escamosa (xerosis) e ictiosis tales agentes pueden aliviar los síntomas de alivio temporal de la comezón asociada con estas condiciones.
Antioxidantes/secuestrantes de radicales
Una cantidad eficaz de un antioxidante/secuestrante de radicales se pueden adicionar a las composiciones espumables, por ejemplo, en una cantidad de aproximadamente 0.1% a aproximadamente 10% (peso/peso), o de aproximadamente 1% a aproximadamente 5 % (peso/peso).
Los antioxidantes/secuestrantes de radicales tales como ácido ascórbico (vitamina C) y sales de ácido ascórbico, ésteres de ascorbilo de ácidos grasos, derivados del ácido ascórbico (por ejemplo, fosfato de ascorbilo de magnesio, ascorbil fosfato de sodio, sorbato de ascorbilo), tocoferol (vitamina E ), sorbato de tocoferol, acetato de tocoferol, otros ésteres de tocoferol, ácidos benzoicos hidroxi butilados y sus sales, ácido 6-hidroxi-2,5,7,8-tetrametilcroman-2-carboxílico (disponible comercialmente bajo el nombre comercial Trolox.®), ácido gálico y ésteres alquílicos de ácido gálico, especialmente galato de propilo, ácido úrico y sales de ácido úrico y ésteres de alquilo, ácido sórbico y sales de ácido sórbico, ácido lipoico, aminas (por ejemplo, N, N-dietilhidroxilamina, aminoguanidina), compuestos de sulfhidrilo (por ejemplo, glutatión), ácido dihidroxi fumárico y sales de ácido dihidroxi fumárico, pidolato de lisina, pilolato de arginina, ácido nordihidroguaiarético, bioflavonoides, la curcumina, lisina, metionina, prolina, superóxido dismutasa, silimarina, extractos de té, extractos de piel/semilla de uva, melanina, y extractos de romero se pueden usar.
La espuma es apropiada para el suministro de antioxidantes revitalizantes y protectores de la piel/secuestrantes de radicales. Los ácidos grasos poliinsaturados que contienen ácidos grasos omega-3 y omega-6 (por ejemplo, ácido linoleico y linolénico, ácido gamma-linoleico (GLA), ácido eicosapentaenoico (EPA) y ácido docosahexaenoico (DHA)) son beneficiosos en el tratamiento de la psoriasis y otras condiciones de inflamación de la piel. Del mismo modo, los emolientes y aceites de silicona ejercen efectos de retención de humedad y protectores de la piel sobre la piel. Por lo tanto, se provee una espuma protectora de la piel, en donde el solvente hidrófobo comprende en su totalidad o en parte, un solvente, seleccionado entre el grupo de emolientes, aceite de silicona y aceites, ricos en ácidos grasos insaturados, por lo tanto, proporcionando un efecto terapéutico sinérgico de los antioxidantes/agentes secuestrantes de radicales y los componentes del vehículo.
Agentes activos autobronceadores
La composición de espuma es apropiada para el suministro uniforme de un agente activo de bronceado en grandes áreas de la piel. Las composiciones pueden contener de aproximadamente 0.1% a aproximadamente 20%, o de aproximadamente 2% a aproximadamente 7%, o incluso de aproximadamente 3% a aproximadamente 6% de dihidroxiacetona o cualquier otro compuesto conocido en la técnica como un agente activo de bronceado artificial.
12
E11190124
02-07-2015
(iii) inhibir la enfermedad o trastorno;
- (iv)
- aliviar la enfermedad o trastorno;
- (iv)
- provocar la regresión de la enfermedad;
5
(v) proporcionar un efecto inmunológico beneficioso; 10 (vi) mejorar la calidad de vida de un sujeto afectado por una enfermedad o trastorno; y, en el caso de tratamiento cosmético
(vii) limpieza, embellecimiento, estimular la atracción, o alterar la apariencia sin afectar la estructura o función del cuerpo EJEMPLOS
15
Ejemplo 1 -Producción de composición y soporte de espuma farmacéutico o Cosmético -Método General
El método para la preparación de un soporte de espuma farmacéutico generalmente comprende las siguientes etapas.
20 Etapa 1 -Fase acuosa: El agente gelificante y el agente tensoactivo se disuelven en agua, con agitación. La solución se calienta de 50-70 °C. Los ingredientes activos* cosméticos o farmacéuticos solubles en agua y los opcionales ingredientes solubles en agua se adicionan con agitación a la mezcla de Fase Acuosa.
Etapa 2 -Fase hidrófoba: El solvente hidrófobo se calienta a una misma temperatura. Los agentes activos* cosméticos o
25 farmacéuticos solubles en aceite y los opcionales ingredientes de formulación solubles en aceite se adicionan con agitación a la mezcla de Fase Hidrófoba.
Etapa 3 -La Fase Hidrófoba caliente se vierte gradualmente en la Fase Acuosa caliente, con agitación, seguido por homogeneización Ultraturax. La mezcla se deja enfriar a temperatura ambiente.
30 Etapa 4 -La mezcla, a temperatura ambiente, se adiciona a un recipiente de aerosol, el recipiente se sella y la cantidad apropiada de propelente (aproximadamente 10% de la masa de la composición) se comprime en el recipiente.
* En el caso de ingredientes activos sensibles al calor, adicionar el ingrediente activo con agitación a la mezcla, después de 35 la Etapa 3.
En los siguientes ejemplos, se prepararon las composiciones de espuma como se describe anteriormente y se evaluaron para la calidad de la espuma
40 Ejemplo de Referencia 2 -Composición de espuma de diclofenaco con transcutol
- Componente
- % peso/peso
- Aceite mineral (solvente hidrófobo)
- 6.00
- Miristato de isopropilo (solvente hidrófobo)
- 6.00
- Alcohol estearílico (adyuvante de espuma)
- 1.00
- Goma xantana (agente gelificante)
- 0.30
- Methocel K100M (agente gelificante)
- 0.30
- TWEEN 80 (surfactante)
- 1.00
- MYRJ 49p (surfactante)
- 3.00
- Cocamidopropilbetaína (surfactante)
- 0.50
- Transcutol p (potenciador terapéutico)
- 20.00
- Monoestearato de glicerilo (co-emulsionante)
- 0.50
- Diclofenaco sódico (agente activo)
- 1.00
- Phenonip (conservante)
- 0.30
- Butano/propano (propelente)
- 8.00
- Agua
- A 100.0
- Calidad de Espuma
- E
- Densidad
- 0.028
17
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49764803P | 2003-08-25 | 2003-08-25 | |
US497648P | 2003-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2541488T3 true ES2541488T3 (es) | 2015-07-21 |
Family
ID=34216139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11190124.5T Expired - Lifetime ES2541488T3 (es) | 2003-08-25 | 2004-08-20 | Espuma farmacéutica penetrante |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050075407A1 (es) |
EP (3) | EP1663148A2 (es) |
JP (1) | JP2007503428A (es) |
KR (1) | KR20060113657A (es) |
CN (1) | CN1856294A (es) |
AU (1) | AU2004266502B2 (es) |
BR (1) | BRPI0412975A (es) |
CA (2) | CA2536482C (es) |
ES (1) | ES2541488T3 (es) |
IL (1) | IL173094A (es) |
MX (1) | MXPA06002163A (es) |
WO (1) | WO2005018530A2 (es) |
ZA (1) | ZA200502180B (es) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US20070292461A1 (en) * | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US20050205086A1 (en) * | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
BR0314916A (pt) | 2002-10-25 | 2005-08-16 | Foamix Ltd | Espuma farmacêutica e cosmética |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20050186142A1 (en) * | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
NZ541526A (en) * | 2003-01-24 | 2008-03-28 | Stiefel Res Australia Pty Ltd | Clindamycin phosphate foam |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
GB0323908D0 (en) * | 2003-10-11 | 2003-11-12 | Nupharm Lab Ltd | Pharmaceutical foam formulation |
ZA200507019B (en) * | 2004-04-28 | 2008-02-27 | Foamix Ltd | Body cavity foams |
KR20070034524A (ko) | 2004-05-28 | 2007-03-28 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린 수용체 조정자 |
WO2006010589A2 (en) * | 2004-07-29 | 2006-02-02 | Mipharm S.P.A. | Post foaming gel mousse |
DE602005019533D1 (de) * | 2005-03-04 | 2010-04-08 | Tecnimede Sociedade Tecnico Medicinal Sa | Pharmazeutische Zusammensetzung enthaltend in Assoziation Ubidecarenon, Dexpanthenol und Chlorhexidine oder eines seiner pharmazeutischen unbedenklichen Salze zur Anwendung auf der Haut |
JP2008540511A (ja) * | 2005-05-09 | 2008-11-20 | フォーミックス エルティーディー. | 糖類発泡性組成物 |
EP1917072B1 (en) * | 2005-06-01 | 2013-02-27 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
EP1919449A2 (en) * | 2005-06-07 | 2008-05-14 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
WO2007085902A2 (en) * | 2005-07-19 | 2007-08-02 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
DE202005011885U1 (de) * | 2005-07-28 | 2006-08-31 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Geschäumte Zubereitung |
FR2890560B1 (fr) * | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation |
FR2890559B1 (fr) * | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour la preparation |
WO2007050543A2 (en) * | 2005-10-24 | 2007-05-03 | Collegium Pharmaceutical, Inc. | Topical pharmaceutical foam composition |
US9308181B2 (en) | 2006-03-06 | 2016-04-12 | Nuvo Research Inc. | Topical formulations, systems and methods |
US9642912B2 (en) | 2006-03-06 | 2017-05-09 | Crescita Therapeutics Inc. | Topical formulations for treating skin conditions |
WO2008007224A2 (en) | 2006-03-31 | 2008-01-17 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
WO2008075207A2 (en) * | 2006-04-04 | 2008-06-26 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
WO2008110872A2 (en) * | 2006-06-23 | 2008-09-18 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
FR2911781B1 (fr) * | 2007-01-26 | 2009-03-20 | Fabre Pierre Dermo Cosmetique | Emulsion dermatologique et procede de preparation |
PL1986473T3 (pl) * | 2007-04-03 | 2017-07-31 | Tsinghua University | Organiczne urządzenie elektroluminescencyjne |
EP2393301A1 (en) | 2007-06-11 | 2011-12-07 | Samsung Electronics Co., Ltd. | Method and apparatus for generating header information of stereoscopic image |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009056991A2 (en) | 2007-09-04 | 2009-05-07 | Foamix Ltd. | Device for delivery of a foamable composition |
WO2009060629A1 (ja) * | 2007-11-11 | 2009-05-14 | Medrx Co., Ltd. | リドカインテープ剤 |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
EA201070690A1 (ru) | 2007-12-06 | 2010-10-29 | Унилевер Н.В. | Композиция для личного ухода |
WO2009071408A1 (en) | 2007-12-06 | 2009-06-11 | Unilever Plc | Personal care composition |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9314524B2 (en) * | 2007-12-31 | 2016-04-19 | Calla Therapeutics Llc | Topical formulations of Flucytosine |
WO2009090558A2 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
EP2143421A1 (en) * | 2008-07-07 | 2010-01-13 | Almirall Hermal GmbH | Topical composition for the treatment of actinic keratosis |
EP2246034A2 (en) * | 2008-10-10 | 2010-11-03 | Unilever PLC | Use of personal care composition |
CN102245169A (zh) * | 2008-10-15 | 2011-11-16 | 昆诺瓦制药公司 | 水杨酸组合物 |
PT2210588E (pt) * | 2008-12-23 | 2011-06-07 | Intendis Gmbh | Composição expansível, essencialmente isenta de ingredientes farmaceuticamente activos para o tratamento da pele humana |
US9012477B2 (en) * | 2009-01-06 | 2015-04-21 | Nuvo Research Inc. | Method of treating neuropathic pain |
WO2010085589A2 (en) | 2009-01-22 | 2010-07-29 | G&H Brands Llc | Desensitizing drug product |
US9676696B2 (en) | 2009-01-29 | 2017-06-13 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
SG173563A1 (en) * | 2009-02-25 | 2011-09-29 | Stiefel Res Australia Pty Ltd | Topical foam composition |
WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011014850A2 (en) * | 2009-07-31 | 2011-02-03 | Nuvo Research Inc. | Topical eutectic-based formulations |
WO2011064631A1 (en) | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
CN102770123A (zh) | 2009-12-23 | 2012-11-07 | 纽沃研究股份有限公司 | 用于治疗甲癣的高渗透性特比萘芬制剂 |
AU2011205730C1 (en) * | 2010-01-14 | 2014-10-09 | Nuvo Research Inc. | Solid-forming local anesthetic formulations for pain control |
CN102869345B (zh) | 2010-03-17 | 2015-02-11 | 诺瓦利克有限责任公司 | 用于治疗眼内压增高的药物组合物 |
AU2010351562B2 (en) * | 2010-04-21 | 2013-10-10 | Teikoku Pharma Usa, Inc. | Local anesthetic emulsion compositions and methods of making and using the same |
EP2409683A1 (en) * | 2010-07-06 | 2012-01-25 | KRKA, D.D., Novo Mesto | Stable aqueous formulations comprising poorly water soluble active ingredients |
WO2012007843A2 (en) | 2010-07-12 | 2012-01-19 | Foamix Ltd. | Apparatus and method for releasing a unit dose of content from a container |
WO2012010942A2 (en) * | 2010-07-22 | 2012-01-26 | Lupin Limited | Novel pharmaceutical composition(s) of hiv protease inhibitor(s) |
US20130165880A1 (en) | 2010-09-17 | 2013-06-27 | David T. Amos | Antimicrobial disposable absorbent articles |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
AU2012260787B2 (en) * | 2011-05-25 | 2017-02-02 | Dermaliq Therapeutics, Inc. | Topical pharmaceutical composition based on semifluorinated alkanes |
US9089129B2 (en) * | 2011-10-07 | 2015-07-28 | American Sterilizer Company | Non-aerosol foaming alcohol hand sanitizer |
CN102416018A (zh) * | 2011-10-13 | 2012-04-18 | 嘉兴富特吉生物科技有限公司 | 一种用含曲安奈德的制剂治疗宫颈糜烂的方法 |
FR2983731B1 (fr) * | 2011-12-07 | 2014-04-25 | Univ Paris Descartes | Emulsions topiques a base de melanges eutectiques d'anesthesiques locaux et d'acide gras |
CN104066442B (zh) | 2012-01-23 | 2018-05-18 | 诺瓦利克有限责任公司 | 基于半氟化烷烃的稳定蛋白质组合物 |
CN102579276B (zh) * | 2012-03-28 | 2013-04-10 | 湖北美林药业有限公司 | 一种化妆品用促渗组合物 |
PT3072510T (pt) | 2012-03-30 | 2019-08-22 | Micelle Biopharma Inc | Composições de éster de ácido gordo ómega-3 |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
ES2965828T3 (es) | 2012-09-12 | 2024-04-17 | Novaliq Gmbh | Composiciones de alcano semifluorado |
WO2014041055A1 (en) | 2012-09-12 | 2014-03-20 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
WO2014095289A2 (en) * | 2012-12-20 | 2014-06-26 | Unilever Plc | Method of treating hair ageing |
ZA201401683B (en) * | 2013-03-08 | 2017-06-28 | Cipla Ltd | Pharmaceutical compositions for rectal administration |
KR102272568B1 (ko) | 2013-07-23 | 2021-07-05 | 노바리크 게엠베하 | 안정화 항체 조성물 |
JP5671118B1 (ja) * | 2013-10-09 | 2015-02-18 | 近代化学株式会社 | 有害動物の忌避用発泡性組成物 |
US9895311B2 (en) * | 2014-09-25 | 2018-02-20 | Pharmiva Ab | Foam-forming compositions and methods for delivering an active to a body cavity |
CN104324039A (zh) * | 2014-10-20 | 2015-02-04 | 付茜 | 一种治疗人身体表面脂肪瘤的药剂及使用方法 |
CN105497601A (zh) * | 2014-11-27 | 2016-04-20 | 印文敏 | 一种治疗牙源性角化囊肿的中药 |
KR102584063B1 (ko) | 2015-09-30 | 2023-09-27 | 노바리크 게엠베하 | 부분불소화 화합물 |
PT3355990T (pt) | 2015-09-30 | 2019-09-11 | Novaliq Gmbh | Compostos semifluorados e as suas composições |
KR20220082095A (ko) | 2015-10-30 | 2022-06-16 | 팀버 파마슈티칼스 엘엘씨 | 이소트레티노인 제형 및 이의 용도 및 사용 방법 |
CN105497340A (zh) * | 2015-12-31 | 2016-04-20 | 张光勤 | 一种痔疮膏及其制备方法,痔疮膏套装 |
CN105557752A (zh) * | 2016-03-03 | 2016-05-11 | 佛山市正典生物技术有限公司 | 一种水杨酸碘泡沫型消毒剂及其制备方法 |
US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
ES2965677T3 (es) | 2016-09-23 | 2024-04-16 | Novaliq Gmbh | Composiciones oftálmicas que comprenden ciclosporina |
EP3554473A1 (en) * | 2016-12-16 | 2019-10-23 | Ferring B.V. | Rectal foam formulations |
US11273174B2 (en) | 2017-04-21 | 2022-03-15 | Novaliq Gmbh | Iodine compositions |
EP3621601A1 (en) | 2017-05-12 | 2020-03-18 | Novaliq GmbH | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
DK3628002T3 (da) * | 2017-05-23 | 2023-06-06 | Pharmiva Ab | Skumdannende sammensætninger til fremføring af et aktivt stof til en legemshulhed |
KR102002283B1 (ko) * | 2017-09-05 | 2019-07-23 | 코스맥스 주식회사 | 병풀 추출물의 공융 혼합물을 포함하는 조성물 |
SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
CA3076567A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | Ophthalmic compositions |
CN107823178B (zh) * | 2017-11-13 | 2021-02-26 | 福建卫生职业技术学院 | 治疗肠易激综合征的尼氟酸结肠靶向制剂及其制备方法 |
CA3082727A1 (en) * | 2017-11-14 | 2019-05-23 | Profem Gmbh | Emulsions for the topical treatment of dermal and mucosal infections |
WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
GB201813876D0 (en) | 2018-08-24 | 2018-10-10 | Antibiotx As | Treatment |
CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
CA3111870C (en) | 2018-09-27 | 2022-04-12 | Novaliq Gmbh | Topical sunscreen formulation |
AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
WO2020089467A1 (en) | 2018-11-02 | 2020-05-07 | UNION therapeutics A/S | Dosage regimen |
CN113347977A (zh) | 2018-11-02 | 2021-09-03 | 联合疗法公司 | 用于治疗皮炎症状的卤代水杨酰苯胺 |
KR20220148884A (ko) * | 2020-03-02 | 2022-11-07 | 이엘씨 매니지먼트 엘엘씨 | 화장제의 전달, 조성물 및 이의 용도 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
CN112405939A (zh) * | 2020-11-07 | 2021-02-26 | 江苏特伟尔斯新材料有限公司 | 一种废弃泡沫塑料回收利用工艺 |
CN115869209A (zh) * | 2021-09-29 | 2023-03-31 | 株式会社Lg生活健康 | 包含维生素c的低共熔混合物的化妆料组合物 |
CN115463044B (zh) * | 2021-10-19 | 2023-12-08 | 广州花出见生物科技有限公司 | 一种含有超分子壬二酸的提亮组合物及其制备方法 |
CN116440110B (zh) * | 2023-03-08 | 2024-01-09 | 广东药科大学 | 托品酸及其衍生物在制备免疫与炎症相关疾病治疗药物中的医药用途 |
CN118831048B (zh) * | 2024-06-21 | 2025-04-08 | 江苏知原药业股份有限公司 | 一种米诺地尔外用溶液及其一锅法制备方法 |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3144386A (en) * | 1958-05-09 | 1964-08-11 | Merck & Co Inc | Mastitis aerosol foam |
GB922930A (en) * | 1959-09-21 | 1963-04-03 | Sunnen Joseph | Spermicidal composition and method of making same |
US3298919A (en) * | 1962-12-26 | 1967-01-17 | Dow Corning | Shaving cream containing polysiloxanes |
US3236457A (en) * | 1963-08-21 | 1966-02-22 | John R Kennedy | Composite spray container assembly |
US3303970A (en) * | 1964-07-14 | 1967-02-14 | Jerome Marrow | Device for simultaneously dispensing from plural sources |
GB1121358A (en) * | 1965-10-21 | 1968-07-24 | Bristol Myers Co | Aerosol manufacture |
US3563098A (en) * | 1968-06-28 | 1971-02-16 | Rex Chainbelt Inc | Automatic quick release mechanism |
US3559890A (en) * | 1968-09-03 | 1971-02-02 | William R Brooks | Foam dispenser |
US3866800A (en) * | 1969-02-12 | 1975-02-18 | Alberto Culver Co | Non-pressurized package containing self-heating products |
US4001391A (en) * | 1969-04-18 | 1977-01-04 | Plough, Inc. | Means for depositing aerosol sprays in buttery form |
JPS5715147B2 (es) * | 1972-03-09 | 1982-03-29 | ||
US4439416A (en) * | 1973-03-23 | 1984-03-27 | Colgate-Palmolive Company | Self-heating shaving composition |
US3865275A (en) * | 1973-07-30 | 1975-02-11 | Raymond Lee Organization Inc | Apparatus for operating an aerosol can |
US4145411A (en) * | 1974-09-05 | 1979-03-20 | Colgate-Palmolive Company | Pressurized foaming shaving composition |
US4310510A (en) * | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
JPS5569682A (en) * | 1978-11-20 | 1980-05-26 | Toyo Aerosol Kogyo Kk | Foam shrinkable composition |
US4439441A (en) * | 1979-01-11 | 1984-03-27 | Syntex (U.S.A.) Inc. | Contraceptive compositions and methods employing 1-substituted imidazole derivatives |
US4309995A (en) * | 1980-01-28 | 1982-01-12 | Sacco Susan M | Vaginal irrigation apparatus |
JPS56135416A (en) * | 1980-03-27 | 1981-10-22 | Mitsubishi Chem Ind Ltd | Pharmaceutical preparation for skin |
LU83876A1 (fr) * | 1982-01-15 | 1983-09-02 | Oreal | Composition cosmetique destinee au traitement des fibres keratiniques et procede de traitement de celles-ci |
GB8330969D0 (en) * | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
US4985459A (en) * | 1984-02-08 | 1991-01-15 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US5002680A (en) * | 1985-03-01 | 1991-03-26 | The Procter & Gamble Company | Mild skin cleansing aerosol mousse with skin feel and moisturization benefits |
DE3670569D1 (de) * | 1985-03-01 | 1990-05-31 | Procter & Gamble | Milder reinigungsschaum. |
DE3521713A1 (de) * | 1985-06-18 | 1986-12-18 | Henkel KGaA, 4000 Düsseldorf | Oel-in-wasser-emulsionen mit verbessertem viskositaetsverhalten |
US4806262A (en) * | 1985-08-14 | 1989-02-21 | The Procter & Gamble Company | Nonlathering cleansing mousse with skin conditioning benefits |
US4906453A (en) * | 1986-08-12 | 1990-03-06 | Jumpeer Nails, Inc. | Mousse product |
DE3628531A1 (de) * | 1986-08-22 | 1988-02-25 | Merz & Co Gmbh & Co | Verschaeumbare cremes |
JPH0778019B2 (ja) * | 1986-11-08 | 1995-08-23 | 久光製薬株式会社 | 泡状エアゾ−ル消炎鎮痛製剤 |
US4898246A (en) * | 1987-07-06 | 1990-02-06 | Total Walther Feuerschutz Gmbh | Quick release valve for sprinkler head |
US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
ES2017587T3 (es) * | 1987-09-23 | 1994-10-16 | Oreal | Composicion de tratamiento de la piel en forma de espuma aerosol que contiene vaselina. |
US4981677A (en) * | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US5143717A (en) * | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
US5378730A (en) * | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
US4902281A (en) * | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US5204093A (en) * | 1989-04-06 | 1993-04-20 | Victor Steven A | Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same |
GB8909559D0 (en) * | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
US5002540A (en) * | 1989-05-22 | 1991-03-26 | Warren Kirschbaum | Intravaginal device and method for delivering a medicament |
US4981367A (en) * | 1989-07-28 | 1991-01-01 | Stranco, Inc. | Portable mixing apparatus |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5091111A (en) * | 1990-09-19 | 1992-02-25 | S. C. Johnson & Son, Inc. | Aqueous emulsion and aersol delivery system using same |
FR2668927B1 (fr) * | 1990-11-09 | 1993-01-08 | Oreal | Composition cosmetique anhydre sous forme aerosol pour la formation d'une mousse. |
US5227163A (en) | 1991-01-18 | 1993-07-13 | Clilco, Ltd. | Lice-repellant compositions |
JPH04282311A (ja) * | 1991-03-08 | 1992-10-07 | Koike Kagaku Kk | エアゾール型発泡性傷口消毒剤 |
US5389676A (en) * | 1991-03-22 | 1995-02-14 | E. B. Michaels Research Associates, Inc. | Viscous surfactant emulsion compositions |
DE4210165A1 (de) * | 1991-07-30 | 1993-02-04 | Schering Ag | Transdermale therapeutische systeme |
GB9118028D0 (en) * | 1991-08-21 | 1991-10-09 | Secr Defence Brit | Improved transdrmal formulations |
IL105595A0 (en) * | 1992-05-15 | 1993-09-22 | Akzo Nv | Applicator for introducing a cream-type substance into a woman's vagina |
ES2101330T3 (es) * | 1992-07-28 | 1997-07-01 | Procter & Gamble | Composicion farmaceutica para uso topico que contiene un polimero cationico reticulado y un eter alcoxilado. |
JP3328344B2 (ja) * | 1992-12-22 | 2002-09-24 | タイホー工業株式会社 | 発泡型洗浄艶出し剤の発泡状態保持時間を制御する方法 |
EP0698393B1 (en) * | 1993-05-19 | 2002-07-03 | Hisamitsu Pharmaceutical Co., Inc. | 3-l-MENTHOXY-PROPANE-1, 2-DIOL AS SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME |
US5398846A (en) * | 1993-08-20 | 1995-03-21 | S. C. Johnson & Son, Inc. | Assembly for simultaneous dispensing of multiple fluids |
JP2978043B2 (ja) * | 1993-09-16 | 1999-11-15 | 高砂香料工業株式会社 | (2s)−3−{(1r,2s,5r)−[ 5−メチル−2−(1−メチルエチル)シクロヘキシル ]オキシ}−1,2−プロパンジオール,その製造方法および用途 |
FR2713486B1 (fr) * | 1993-12-14 | 1996-02-09 | Scophysa | Nouvelles compositions pour mousses, notamment mousses rectales, et mousses ainsi obtenues. |
ES2079320B1 (es) * | 1994-05-17 | 1996-10-16 | Cusi Lab | Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones. |
US5902574A (en) * | 1994-05-23 | 1999-05-11 | The Gillette Company | Shaving preparation for improved shaving comfort |
FR2722431B1 (fr) * | 1994-07-12 | 1996-09-13 | Lir France Sa | Distributeur double pour produits fluides |
JP3173330B2 (ja) * | 1994-07-20 | 2001-06-04 | トヨタ自動車株式会社 | 車両用ロックアップクラッチのスリップ制御装置 |
US5869529A (en) * | 1994-07-20 | 1999-02-09 | Agis Industries (1983) Ltd. | Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
US5512555A (en) * | 1994-07-21 | 1996-04-30 | Merck & Co., Inc. | Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one |
GB9414699D0 (en) * | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
DE4428096A1 (de) * | 1994-08-09 | 1996-02-15 | Wella Ag | Zweikammerbehälter |
GB9424562D0 (en) * | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
US5616136A (en) * | 1995-01-09 | 1997-04-01 | Med-Safe Systems, Inc. | Quick release needle removal apparatus |
GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
EP0738510A3 (fr) * | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
FR2742986B1 (fr) * | 1995-12-29 | 1998-01-30 | Rhone Poulenc Chimie | Compositions cosmetiques pour le cheveu ou la peau a base de copolyesters sulfones a motifs polyorganosiloxanes |
US5716611A (en) * | 1996-01-02 | 1998-02-10 | Euro-Celtique, S.A. | Emollient antimicrobial formulations containing povidone iodine |
US5759524A (en) * | 1996-02-09 | 1998-06-02 | The Procter & Gamble Company | Photoprotective compositions |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
FR2754451B1 (fr) * | 1996-10-14 | 1998-11-06 | Oreal | Creme auto-moussante |
BR9707147A (pt) * | 1996-11-16 | 1999-04-06 | Wella Ag | Agente para o tingimento e descoloraç o de fibras |
US5856452A (en) * | 1996-12-16 | 1999-01-05 | Sembiosys Genetics Inc. | Oil bodies and associated proteins as affinity matrices |
US6582711B1 (en) * | 1997-01-09 | 2003-06-24 | 3M Innovative Properties Company | Hydroalcoholic compositions thickened using polymers |
IN186803B (es) * | 1997-02-05 | 2001-11-10 | Panacea Biotec Ltd | |
US6183762B1 (en) * | 1997-05-27 | 2001-02-06 | Sembiosys Genetics Inc. | Oil body based personal care products |
US6423323B2 (en) | 1997-08-18 | 2002-07-23 | Stephanie Neubourg | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
US6024285A (en) * | 1997-08-19 | 2000-02-15 | Micron Technology, Inc. | Wireless communication devices and methods of forming wireless communication devices |
US5865347A (en) * | 1997-10-27 | 1999-02-02 | William T. Wilkinson | Multi-chamber dispenser for flowable materials |
US6110966A (en) * | 1998-02-20 | 2000-08-29 | Medi-Cell Laboratories, Inc. | Triple action complex |
DE19807774A1 (de) * | 1998-02-24 | 1999-08-26 | Beiersdorf Ag | Verwendung von Flavonen bzw. Flavanonen bzw. Flavonoiden zum Schutze von Ascorbinsäure und/oder Ascorbylverbindungen gegen Oxidation |
AUPP583198A0 (en) * | 1998-09-11 | 1998-10-01 | Soltec Research Pty Ltd | Mousse composition |
RU2134052C1 (ru) * | 1998-10-07 | 1999-08-10 | Нерушай Сергей Алексеевич | Способ аэрозольного нанесения парфюмерных жидкостей и устройство для его осуществления |
US6344218B1 (en) * | 1998-11-23 | 2002-02-05 | The Procter & Gamble Company | Skin deodorizing and santizing compositions |
FR2787325B1 (fr) * | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
FR2788007B1 (fr) * | 1999-01-05 | 2001-02-09 | Oreal | Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
FR2789371B1 (fr) * | 1999-02-05 | 2001-04-27 | Sofab | Distributeur de produits chimiquement instables |
US6168576B1 (en) * | 1999-05-24 | 2001-01-02 | Irene N. Reynolds | Device for dispensing vaginal medication |
US6190365B1 (en) * | 1999-06-21 | 2001-02-20 | Chun Lim Abbott | Vaginal douche applicator and method of vaginal deodorization using the same |
US6524594B1 (en) * | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
AU5764800A (en) * | 1999-07-01 | 2001-01-22 | Johnson & Johnson Consumer Companies, Inc. | Cleansing compositions |
DE19938757A1 (de) * | 1999-08-16 | 2001-02-22 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen vom Typ Öl-in-Wasser |
US6528086B2 (en) * | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
US6186367B1 (en) * | 1999-10-19 | 2001-02-13 | Valley Design Inc. | Metered liquid squeeze dispenser |
US20030077301A1 (en) * | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
US6967023B1 (en) * | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
IL133969A0 (en) * | 2000-01-10 | 2001-04-30 | Thixo Ltd | Thixotropic compositions containing unsaturated oils and food products containing the same |
DE20006099U1 (de) * | 2000-04-01 | 2000-07-06 | MegaPlast GmbH & Co. KG, 78052 Villingen-Schwenningen | Dosierpumpenspender mit wenigstens zwei Dosierpumpen |
JP2002012513A (ja) * | 2000-04-24 | 2002-01-15 | Kanebo Ltd | 尿素含有ホイップ状化粧料 |
US6358541B1 (en) | 2000-05-03 | 2002-03-19 | David S. Goodman | Topical preparation for the treatment of hair loss |
US6410036B1 (en) * | 2000-05-04 | 2002-06-25 | E-L Management Corp. | Eutectic mixtures in cosmetic compositions |
JP4653282B2 (ja) * | 2000-05-23 | 2011-03-16 | 昭和薬品化工株式会社 | ミノサイクリン含有組成物 |
US6514487B1 (en) * | 2000-08-08 | 2003-02-04 | Teresa Leigh Barr | Foam and gel oat protein complex and method of use |
DE10058384B4 (de) * | 2000-11-24 | 2004-12-16 | Wella Aktiengesellschaft | Kosmetisches oder dermatologisches Mittel in Form eines cremigen Permanentschaums oder einer stabil aufgeschäumten Creme, deren Verwendung und Verfahren zur Herstellung des Mittels |
US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
US6682726B2 (en) * | 2001-04-30 | 2004-01-27 | The Gillette Company | Self-foaming shaving lotion |
JP2003012511A (ja) * | 2001-06-27 | 2003-01-15 | Rohto Pharmaceut Co Ltd | エアゾール組成物 |
US7002483B2 (en) * | 2001-07-11 | 2006-02-21 | Trw Inc. | Configurable arrangement of multiple transmitters and multiple receivers for the performance of remote convenience functions |
US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
US6691898B2 (en) * | 2002-02-27 | 2004-02-17 | Fomo Products, Inc. | Push button foam dispensing device |
WO2003078075A1 (en) * | 2002-03-19 | 2003-09-25 | Airspray International B. V. | Dispensing unit |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
BR0314916A (pt) * | 2002-10-25 | 2005-08-16 | Foamix Ltd | Espuma farmacêutica e cosmética |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20040151756A1 (en) * | 2003-02-04 | 2004-08-05 | Richards Anthony P. | Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle |
US6843390B1 (en) * | 2003-03-17 | 2005-01-18 | Joe G. Bristor | Multiple fluid closed system dispensing device |
US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
US7735914B2 (en) * | 2003-07-29 | 2010-06-15 | L & P Property Management Company | Ottoman recliner |
CA2540085C (en) * | 2003-09-29 | 2010-11-16 | Bruce Michael Koivisto | High alcohol content gel-like and foaming compositions |
US20060008432A1 (en) * | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
US7288692B2 (en) * | 2004-07-14 | 2007-10-30 | Exxonmobil Chemcial Patents Inc. | Process for producing olefins |
JP2008540511A (ja) * | 2005-05-09 | 2008-11-20 | フォーミックス エルティーディー. | 糖類発泡性組成物 |
US20070009607A1 (en) * | 2005-07-11 | 2007-01-11 | George Jones | Antibacterial/anti-infalmmatory composition and method |
CN100531515C (zh) * | 2005-07-22 | 2009-08-19 | 鸿富锦精密工业(深圳)有限公司 | 具有改良电源区块的印刷电路板 |
JP2009504805A (ja) * | 2005-08-09 | 2009-02-05 | ナノバイオ コーポレーション | 抗炎症活性を有するナノエマルジョン組成物 |
US7826675B2 (en) * | 2006-07-04 | 2010-11-02 | Hewlett-Packard Development Company, L.P. | Feature-aware image defect removal |
MX2009000507A (es) * | 2006-07-14 | 2009-06-12 | Stiefel Res Australia Pty Ltd | Espuma farmaceutica de acidos grasos. |
ES2330291B1 (es) * | 2008-02-29 | 2010-10-18 | Lipotec Sa | Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. |
-
2004
- 2004-08-20 EP EP04769356A patent/EP1663148A2/en not_active Withdrawn
- 2004-08-20 KR KR1020067003853A patent/KR20060113657A/ko not_active Withdrawn
- 2004-08-20 CA CA2536482A patent/CA2536482C/en not_active Expired - Fee Related
- 2004-08-20 CA CA2776692A patent/CA2776692C/en not_active Expired - Fee Related
- 2004-08-20 JP JP2006524466A patent/JP2007503428A/ja active Pending
- 2004-08-20 ES ES11190124.5T patent/ES2541488T3/es not_active Expired - Lifetime
- 2004-08-20 WO PCT/IB2004/002965 patent/WO2005018530A2/en active Application Filing
- 2004-08-20 AU AU2004266502A patent/AU2004266502B2/en not_active Ceased
- 2004-08-20 EP EP15163245.2A patent/EP2977043A3/en not_active Withdrawn
- 2004-08-20 US US10/922,555 patent/US20050075407A1/en not_active Abandoned
- 2004-08-20 EP EP11190124.5A patent/EP2422768B1/en not_active Expired - Lifetime
- 2004-08-20 MX MXPA06002163A patent/MXPA06002163A/es active IP Right Grant
- 2004-08-20 BR BRPI0412975-0A patent/BRPI0412975A/pt not_active IP Right Cessation
- 2004-08-20 CN CNA2004800277752A patent/CN1856294A/zh active Pending
-
2006
- 2006-01-11 IL IL173094A patent/IL173094A/en active IP Right Grant
- 2006-03-15 ZA ZA200502180A patent/ZA200502180B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2977043A3 (en) | 2016-04-06 |
MXPA06002163A (es) | 2006-05-22 |
CN1856294A (zh) | 2006-11-01 |
CA2776692A1 (en) | 2005-03-03 |
US20050075407A1 (en) | 2005-04-07 |
IL173094A0 (en) | 2009-02-11 |
BRPI0412975A (pt) | 2006-10-03 |
EP2422768A3 (en) | 2012-05-09 |
KR20060113657A (ko) | 2006-11-02 |
JP2007503428A (ja) | 2007-02-22 |
AU2004266502B2 (en) | 2010-09-23 |
WO2005018530A3 (en) | 2005-10-20 |
CA2536482A1 (en) | 2005-03-03 |
WO2005018530A2 (en) | 2005-03-03 |
EP2422768B1 (en) | 2015-04-15 |
ZA200502180B (en) | 2006-06-28 |
EP2977043A2 (en) | 2016-01-27 |
CA2536482C (en) | 2012-07-24 |
EP1663148A2 (en) | 2006-06-07 |
IL173094A (en) | 2012-02-29 |
AU2004266502A1 (en) | 2005-03-03 |
EP2422768A2 (en) | 2012-02-29 |
CA2776692C (en) | 2014-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2541488T3 (es) | Espuma farmacéutica penetrante | |
KR102560269B1 (ko) | 약제학적 조성물 | |
US9622947B2 (en) | Foamable composition combining a polar solvent and a hydrophobic carrier | |
US20100021405A1 (en) | External preparation for skin | |
WO2007085902A2 (en) | Foamable composition combining a polar solvent and a hydrophobic carrier | |
JP6352560B2 (ja) | アスコルビン酸及び/又はその塩を含有する外用組成物 | |
JP7153429B2 (ja) | 活性酸素消去剤 | |
EP2004162A1 (en) | Use of polyamines in the treatment of psoriasis | |
JP2016130224A (ja) | 外用組成物 | |
JP6851998B2 (ja) | 多相組成物 | |
JP2019006697A (ja) | 活性酸素消去剤 | |
JP2008074780A (ja) | リポソームの皮膚吸収部位をコントロールする方法及びリポソームの皮膚吸収コントロールリリース剤 | |
JP2017114895A (ja) | 多価不飽和脂肪酸含有組成物 | |
KR20220010508A (ko) | 안정적인 화장료 조성물을 제조하기 위한 제형 및 방법 | |
JP5241054B2 (ja) | コラーゲン合成促進用組成物 | |
JP7047261B2 (ja) | アシルプロリンを含むベシクルを有する組成物 | |
JP4683861B2 (ja) | 皮膚外用剤 | |
JP2005263794A (ja) | コラーゲン合成促進用組成物 | |
BR102014033159A2 (pt) | formulações nutricosméticas para a minimização dos efeitos do processo de envelhecimento humano utilizando biomassa e/ou extrato de microalga(s) e /ou cianobactéria(s) na forma isolada e/ou combinada a outro(s) composto(s) | |
JP5338030B2 (ja) | アダパレン含有外用剤組成物 | |
CN106456598B (zh) | 外用药物组合物 | |
JP2006342098A (ja) | 皮膚外用剤 | |
Arianto et al. | The effect of tween 80, palm kernel oil, and its conversion product on in vitro penetration enhancement of indomethacin through rabbit skin | |
JP5980171B2 (ja) | アダパレン含有外用剤組成物 | |
JP5520703B2 (ja) | コラーゲン合成促進用組成物 |